Advances in Systemic Therapy of Differentiated Thyroid Cancer in Second Line and Beyond

Lori Wirth, MD, provides an overview of differentiated thyroid cancer including treatment options that are currently available, as well as sharing insights on emerging therapies.

EP. 1: Presentation and Disease Course of Differentiated Thyroid Cancer

March 30th 2022

Lori Wirth, MD, provides an overview of differentiated thyroid cancer including patient presentation and disease course.

EP. 2: Frontline Treatment Options for RAI-refractory DTC

April 8th 2022

Lori Wirth, MD, defines radioiodine-refractory differentiated thyroid cancer and discusses frontline treatment options for patients with the disease.

EP. 3: Treatment Options in RAI-refractory DTC in Second Line and Beyond

April 19th 2022

Lori Wirth, MD, discusses the role of cabozantinib in the second-line setting for patients with radioiodine-refractory differentiated thyroid cancer and reviews the results from the COSMIC-311 trial.

EP. 4: Facing Unmet Needs and Ongoing Trials in RR-DTC

April 20th 2022

Lori Wirth, MD, discusses the unmet needs and ongoing trials in development for patients with RR-DTC.

EP. 5: OncView™ Podcast: Advances in Systemic Therapy of Differentiated Thyroid Cancer

May 12th 2022

In an OncView™ program, Lori Wirth, MD, shared her insights into the current treatment of patients with differentiated thyroid cancer.

EP. 6: Recap: Advances in Systemic Therapy of Differentiated Thyroid Cancer Across Lines of Therapy

May 24th 2022

Lori Wirth, MD, provides an overview of differentiated thyroid cancer including treatment options that are currently available, as well as sharing insights on emerging therapies.